First-in-class cancer therapeutic to stimulate natural killer cells
Article Abstract:
The first ever clinical trial of a therapeutic that binds to natural killer (NK) cell receptors is slated to take place before the end of 2006. Its goal is to harness directly the therapeutic potential of NK cells in the treatment of a wide range of immune-related conditions, including cancers, autoimmune disease and infection.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Cancer surgery joins the dots
Article Abstract:
The use of quantum dots in performing sentinel lymph node biopsy (SLNB) through optical imaging near-infrared (NIR) fluorescence is presented. It represents not only a pioneering medical application of nanocrystals, but also a step forward in the clinical application of sentinel lymph node biopsy (SLNB) in cancer surgery.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Erbitux diagnostic latest adjunct to cancer therapy
Article Abstract:
Chimeric antibody Erbitux, which is manufactured by ImClone, has acquired the United States (US) marketing clearance for treating metastatic colorectal cancer. DakoCytomation has received the approval of The US Food and Drug Administration (FDA) for using with Erbitux.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: An engineered epigenetic transgene switch in mammalian cells. Gas-inducible transgene expression in mammalian cells and mice
- Abstracts: India aims to become the main bioinformatics hub. Off the beaten path. E&Y report backs Asia-Pacific biotech
- Abstracts: Convergence in biomedical technology. Engineering vascularized skeletal muscle tissue. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells
- Abstracts: The return of the biotech scorecard. PEGing biotech growth. How do your stocks really perform?
- Abstracts: The biological magic behind the bullets. Structure-based maximal affinity model predicts small-molecule druggability